Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0409974 (
lupus
)
22,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A fetal congenital complete AV-block was detected in the 30th week of gestation. After close sonographic and cardiotocographic follow-up examinations
premature labor
occurred in the 37th week of gestation. The interpretation of the fetal heart rate pattern was difficult. The bradycardia was accompanied by late decelerations (dip II), only different from familiar hypoxia-patterns by the bradycardia. Caesarean section therefore was immediately done. A partial abruptio placentae was found as causing hypoxia. The child developed well after insertion of a temporary transvenous pacemaker. The AV-block is still persisting. At the age of three months the child fell ill of an acute cutaneous
lupus erythematosus
. The symptoms disappeared after unspecific treatment. Antinuclear antibodies pathognomonic for
lupus erythematosus
were traceable in the symptomless mother. There are other observations of motherly autoantibodies passing the placental barrier impairing the fetal heart conduction.
...
PMID:[Problem of fetal arrhythmias--a case report]. 399 38
Systemic lupus erythematosus (SLE) is a connective tissue disease ranked as an autoimmune background illness. Due to the fact, that 90% of
lupus
suffering patients are women in childbearing age, SLE is relatively common in pregnancy. SLE exerts negative influence on pregnancy course and perinatal period, significantly increasing a risk of spontaneous abortions, intrauterine fetal growth restrictions, fetal mortality in second trimester and
premature labour
. The increase of perinatal mortality is usually a consequence of diffuse nephritis, hypertension or presence of antiphospholipid antibodies. Women with SLE belong to high-risk pregnancy group, need special care and delivery should take place in hospital conditions exclusively. In our paper we present an epidemiological aspect and complicated issue of diagnostic and therapeutic approaches of pregnant women suffering from SLE with special focus on current care standards and treatment recommendations.
...
PMID:[Systemic lupus erythematosus (SLE)]. 1737 31
Pregnancy in patients with systemic lupus erythematosus (SLE) is considered a high-risk pregnancy. It is complicated by preeclampsia,
premature labour
and miscarriage more frequently than in the general population. Improved prognosis depends on low disease activity during conception and on appropriate medical care (SLE activity monitoring, selection of therapy safe for the mother and the developing foetus, advances in neonatology). Because symptoms of physiological pregnancy and SLE exacerbation are similar, their correct interpretation is essential for skin lesions, arthralgias, arterial hypertension or results of laboratory tests: proteinuria, thrombocytopenia or leucopenia observed in the patient. In order to standardise the assessment of SLE activity during pregnancy, scores of this activity are used. In the past, scores validated on non-pregnant populations (including male patients) were used: Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Systemic
Lupus
Activity Measure (SLAM), European Consensus
Lupus
Activity Measurment (ECLAM). Only recently have SLE activity scores been introduced that are specific for pregnant women:
Lupus
Activity Index In Pregnancy (LAI-P), Systemic Lupus Erythematosus Pregnancy Disease Activity Index (SLEPDAI), modified--Systemic
Lupus
Activity Measure (m-SLAM) and a visual three-grade score modified--Physician Global Assessment (m-PGA). So far, only scores LAI-P and m-PGA have been validated. According to the LAI-P score, clinical data are divided into 4 groups. Group 1 includes mild clinical symptoms, group 2--symptoms of involvement of internal organs, group 3 pertains to modifications of treatment and group 4 to laboratory parameters. Point values are ascribed to individual parameters depending on their intensity.
...
PMID:[Evaluation of systemic lupus erythematosus activity during pregnancy]. 1796 97